Accuracy Beyond Genetics: How the TOPOGRAPH System is Changing the Treatment of Rare Cancers
In modern oncology, the personalized approach is reaching a new level. Results from the Australian Molecular Screening and Therapeutic (MoST) program published in March 2026 proved that to overcome rare and resistant forms of cancer, it is not enough to simply find a mutation; it is necessary to select a drug with the highest level of evidence.
The key to success has been the TOPOGRAPH framework, which is now considered an important tool in the global practice of precision medicine, including leading oncology centers in Israel.
The Essence of the Breakthrough: The Power of Clinical Evidence
The problem of rare tumors (which account for up to 25% of all cancer cases) lies in the absence of standard protocols. The TOPOGRAPH system classifies treatment options by tiers:
- Tiers 1-3A: drugs whose effectiveness is confirmed by serious clinical trials.
- Tiers 3B/4: experimental data or use of drugs for new indications.
The study showed a dramatic difference in outcomes. Patients receiving therapy with a strong evidence base (Tiers 1-3A) demonstrated a median survival of 21.2 months. In comparison, the median survival for those using nonspecific methods was only 12.8 months.
Send your records — an Ichilov physician will reply within 1–2 days, free of charge.
Israel at the Forefront of Genomic Oncology
Although the study was conducted in Australia, its findings are directly relevant to Israeli medicine. In centers such as Ichilov (Sourasky), genomic profiling of tumors is already routine practice. Israeli oncologists use similar algorithms to analyze the genetic code of tumors to select targeted therapies.
The implementation of TOPOGRAPH-class systems allows doctors in Israel to:
- Minimize risks: exclude the prescription of drugs with a low likelihood of response.
- Accelerate the start of treatment: quickly rank available therapy options.
- Provide a chance for rare forms: find effective solutions where standard chemotherapy is powerless.
“These results confirm the priority of genomic-oriented therapies based on the strength of clinical evidence,” the authors of the study note. This supports the strategy of Israeli institutions, such as the Weizmann Institute, where platforms for ultra-precise drug matching are actively being developed.
What Does This Mean for Patients?
A rare diagnosis no longer means a lack of hope. Thanks to international data exchange and the use of intelligent mutation filtering systems, Israeli clinics can offer patients access to the most advanced protocols.
The integration of such frameworks transforms oncology into a programmable discipline, where every step taken by the physician is backed by a global knowledge base. For international patients choosing treatment in Israel, this means access to therapies that were considered experimental just yesterday, and today save lives based on rigorous evidence standards.